Madrigal Pharmaceuticals Inc’s filing revealed that its Director Taub Rebecca unloaded Company’s shares for reported $0.35 million on Jul 18 ’25. In the deal valued at $350.00 per share,1,000 shares were sold. As a result of this transaction, Taub Rebecca now holds 461,044 shares worth roughly $156.25 million.
Then, FRIEDMAN PAUL A sold 1,400 shares, generating $490,044 in total proceeds. Upon selling the shares at $350.03, the Director now owns 187,164 shares.
Before that, PAUL FRIEDMAN bought 1,400 shares. Madrigal Pharmaceuticals Inc shares valued at $488,222 were divested by the Director at a price of $348.73 per share.
B. Riley Securities upgraded its Madrigal Pharmaceuticals Inc [MDGL] rating to a Buy from a a Neutral in a research note published on February 28, 2025; the price target was increased to $422 from $236. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late February has reiterated a ‘”a Buy”‘ rating for it. Cantor Fitzgerald began covering MDGL with “Neutral” recommendation on June 28, 2024. Wolfe Research started covering the stock on June 11, 2024. It rated MDGL as “an Outperform”.
Price Performance Review of MDGL
On Tuesday, Madrigal Pharmaceuticals Inc [NASDAQ:MDGL] saw its stock jump 8.59% to $338.91. Over the last five days, the stock has gained 15.12%. Madrigal Pharmaceuticals Inc shares have risen nearly 21.70% since the year began. Nevertheless, the stocks have risen 9.83% over the past one year.
How much short interest is there in Madrigal Pharmaceuticals Inc?
A steep rise in short interest was recorded in Madrigal Pharmaceuticals Inc stocks on 2025-07-15, dropping by -0.37 million shares to a total of 3.79 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 4.15 million shares. There was a decline of -9.64%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 22, 2024 when BofA Securities began covering the stock and recommended ‘”an Underperform”‘ rating along with a $150 price target.
